These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1425891)

  • 21. Design of silica carrier for controlled release of molsidomine: effect of preparation methods of silica matrixes and their composites with molsidomine on the drug release kinetics in vitro.
    Parfenyuk EV; Dolinina ES
    Eur J Pharm Biopharm; 2014 Nov; 88(3):1038-45. PubMed ID: 25269886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term antihypertensive effect of delayed-action molsidomine].
    Fach WA; Kostanecka T; Kober G
    Z Kardiol; 1994 Sep; 83(9):646-51. PubMed ID: 7801667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of multiparticulate sustained-release diltiazem preparations in dogs.
    Murata K; Noda K
    J Pharm Sci; 1994 Jan; 83(1):38-41. PubMed ID: 8138907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):163S-169S. PubMed ID: 4005118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic properties of a new sustained-release theophylline preparation.
    Dahlqvist R; Billing B
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of an oral sustained-release diltiazem preparation.
    Murata K; Yamahara H; Kobayashi M; Noda K; Samejima M
    J Pharm Sci; 1989 Nov; 78(11):960-3. PubMed ID: 2621582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
    Ostrowski J; Gaul G; Voegele D; Brockmeier D; Resag K
    Eur J Clin Pharmacol; 1985; 28(5):611-3. PubMed ID: 3899679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium.
    Suleiman MS; Najib N; el-Sayed Y; Hasan M; Abdulahameed M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):276-9. PubMed ID: 2737796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and in vitro/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets.
    Liu Y; Sun Y; Sun J; Zhao N; Sun M; He Z
    Int J Pharm; 2012 Apr; 426(1-2):21-28. PubMed ID: 22266529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Human pharmacokinetics of molsidomine].
    Singlas E; Martre H
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):503-9. PubMed ID: 6364946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
    Karkossa F; Klein S
    J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations.
    Langenbucher F; Mysicka J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):151S-162S. PubMed ID: 4005117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human pharmacokinetics of tiaprofenic acid after regular and sustained release formulations: lack of chiral inversion and stereoselective release.
    Vakily M; Jamali F
    J Pharm Sci; 1994 Apr; 83(4):495-8. PubMed ID: 8046602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.